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SPI Track  
Influenza vaccines really work 
Keeping apart the true from the false 
 
A yearly seasonal flu vaccine is the best preventive method we have against influenza at this 
time. Even so, vaccination adoption is hampered by issues of prejudice and confusion. 
Critical comments also regularly do a disservice to public health. In order to dot the i's and 
cross the t's, at the fifth ESWI Influenza Conference a dedicated SPI Track focused on the 
effectiveness and safety of influenza vaccination.  
 
The reality of flu vaccine use in priority groups 
 
Opening speaker Diane Gross, of the World Health Organization (WHO) Regional Office for 
Europe, set the scene by commenting on the reality of flu vaccine use in priority groups. 
Influenza vaccines were first introduced in the 1940s. They still offer the best means to 
prevent influenza, but vaccine effectiveness varies each year and by target group. WHO 
provides recommendations regarding priority groups for influenza vaccination: pregnant 
women, young children between 6 and 59 months, the elderly, the chronically sick, 
healthcare workers and residents of institutions for the elderly and the disabled. Gross: “The 
majority of these groups are at high risk of severe disease and death. Currently, the greatest 
emphasis is given to pregnant women. In 2012, the Strategic Advisory Group of Experts 
(SAGE) said that if countries start an influenza programme or update their existing 
programme, pregnant women should be included. Pregnant women are at a high risk of 
severe disease or death, especially in combination with an underlying condition such as 
asthma, diabetes or obesity. Flu infection during pregnancy also increases the risk of pre-
term birth, low birth weight, stillbirth and the need for an emergency caesarean. 
Furthermore, as a positive side effect, vaccination of the mother can reduce infection in 
infants until the age of 6 months. Young children are targeted because of their higher rates 
of disease, clinic visits and hospitalizations when compared with adults. Because of their 
contact with family members and other children, they also play a critical role in sustaining 
influenza transmission. Vaccines are safe and effective, but less effective in children under 
the age of 2 years. Also the elderly and the chronically sick are more likely to develop severe 
health issues or fatal disease. In the elderly, hospitalization rates due to influenza are high 
and recovery from infection is long. Influenza outbreaks in recovery homes for the elderly or 
the disabled are common. Healthcare workers are considered as a target group for a 
different reason: the risk of transmitting the infection to vulnerable patients. Given the fact 
that vaccination is safe and effective, vaccination may reduce staff absence rates and 
morbidity and mortality rates in patients.”  
 
“Countries have to figure out how to incorporate these target groups in their flu programs,” 
says Gross. However, national member states cannot be obliged to follow WHO 
recommendations. Consequently, vaccination rates in these risk groups still remain 
suboptimal. WHO organized an electronic survey on vaccine programmes, vaccine uptake 
and monitoring policies in the 2011/2012 season. Gross: “53 countries were invited to 
participate in the Vaccine European New Integrated Collaboration Effort (VENICE) Survey, of 
which 48 responded. From these respondents, 44 countries said that they had vaccines 
available. All recommend vaccination for the elderly and the chronically sick. Healthcare 
workers were also recommended for vaccination, with the exception of Denmark, Sweden 
and Finland. With regard to pregnant women, there is more variability. Very few have 
recommendations in place for this target group. Some countries have recommendations for 
some pregnant women, and some have no recommendations at all; for example, in France, 
the Netherlands, Norway, Finland, Poland, Austria, the Czech Republic, Slovakia, Romania, 
Bulgaria and Turkey. But there is also good news: the number of EU countries with 
recommendations in place has been going up. With regard to recommendations for young 
children, Eurasia is split into two parts, with recommendations largely absent in the western 
part and the eastern part generally recommending vaccination for all children older than 6 
months or for some age groups.”  
 
Collecting accurate information about vaccine uptake remains hampered by the absence of 
monitoring systems. Less than 50 % of the countries with vaccination recommendations for 
pregnant women, the chronically sick, residents of long-term care facilities and healthcare 
workers actually monitor the uptake. Monitoring is mainly focused on the uptake in children 
and the elderly, although the number of countries doing so is still far from optimal. 
According to Diane Gross, failure to monitor vaccine uptake means that it is difficult to 
assess progress. “Of the 41 countries that replied to the survey and had recommendations 
for the elderly, only 28 provided data for the 2011/2012 season. The majority of countries 
did not reach 50 % of the target population. Only one country - the Netherlands - achieved 
the 75% uptake goal set by the WHO.” 
 
However, the evidence that is available suggests, firstly, that the low uptake of vaccines in 
key target groups in some countries is now mainly due to a lack of awareness amongst the 
risk groups themselves. Safety concerns and a lack of positive recommendation from medical 
providers for the elderly and the pregnant are subsidiary factors. Secondly, in order to raise 
vaccine uptake rates, it is necessary for people in target groups to have easy access to 
vaccination. At the same time, it is important to be aware that the limited evidence of the 
effect on mortality in countries with high coverage leads to a loss of public confidence.  
“Despite the strong evidence of the burden and its severity, vaccine uptake remains low,” 
says Gross. “Monitoring adverse events is important if we want to increase trust. We need to 
build a body of evidence.” 
 
Is there not a danger of overcomplicating matters? With so many risk groups, it is difficult for 
countries to organize the implementation of all the various recommendations. A simpler 
approach, like the one the US employs with its universal recommendation, might possibly 
make things easier to absorb; for example, in Europe. Gross: “Universal recommendations 
could be very useful, especially from a complexity point of view. For some countries 
simplification might help. But even then, the prioritizing of certain groups might still be 
necessary.” 
 
The effectiveness issue in elderly patients 
 
The vaccination controversy is primarily about safety and effectiveness. Policy makers want 
certainty. But if even the scientists are unable to provide conclusive answers, it is hardly 
surprising that the policy makers remain confused. And if the evidence is not convincing, 
why have governments not stopped recommending vaccination for the elderly? These were 
the basic questions posed by Jonathan Van Tam of the University of Nottingham.  
 
The root cause of the inability to deliver simple answers to these questions lies in the 
relationship between biological vaccine efficacy and vaccine effectiveness. This relationship 
is a complex one. The situation is further complicated by the fact that vaccination 
effectiveness estimates are also influenced to a large degree by the extent of virus 
circulation, the co-circulation of other pathogens, and measurement biases induced by the 
original study design. Van Tam: “If you have mass vaccination, you suppress the circulation 
of the virus itself.  When the virus is not circulating, the vaccine cannot protect against a 
non-existent entity and thus vaccination effectiveness will tend towards zero and the studies 
will be underpowered. Vaccination effectiveness estimates will also vary according to the 
study outcome. It is very easy to misdiagnose influenza. If laboratory-confirmed influenza 
infection is the outcome, then the study will be as accurate as it possibly can be. If, on the 
other hand, syndromic illness is the outcome, or complications, or mortality, without virus 
confirmation, then these outcomes, being non-specific for influenza, will include outcomes 
that are not due to influenza and are therefore not vaccine preventable, so that 
‘effectiveness’ estimates are reduced, often significantly.” 
 
Early last year, influenza vaccination benefits for the elderly were questioned by the 
Cochrane Collaboration. Van Tam: “With its review of 75 eligible studies, comprising 100 
datasets, 14 different outcomes and 4 sub-groups, Cochrane adopted a highly stratified 
approach. Some errors were made in the assignment of studies to virus circulation or non-
circulation periods. The mosaic of results led to a lack of overall interpretability.” Cochrane 
not only reported that it was ‘unable to reach clear conclusions about the effects of vaccines 
in the elderly’, but also said that influenza vaccine is more effective in frail old people living 
in an assisted nursing environment than the elderly living in the community – a conclusion 
that makes no sense from a biological perspective. In the lay press, this message was further 
simplified and abbreviated to ‘elderly people living in the community should expect no 
benefit from influenza vaccination’, providing fodder for those who say that science and 
vaccines cannot be trusted. 
 
In order to carry out their review, the Cochrane statisticians chose 75 articles from a 
database of 4,000 publications, using mainly observational studies, to perform 100 single 
meta-analyses, according to various vaccine types, study designs, populations and outcome 
case definitions. The Cochrane data analysis failed to successfully distinguish between 
seasons with high, mild or no circulation of an influenza virus. Nor did it make a distinction 
between vaccines with a good or a poor match for the influenza strain circulating at that 
time. Another weakness was the fact that their analyses were guided mainly by formal 
statistical criteria and not by biological criteria.  
 
Encouraged by the invitation of the Cochrane authors to produce ‘any alternative 
interpretation’ of the evidence, a group of scientists comprising Walter E.P. Beyer, Janet 
McElhaney, Arnold Monto, Jonathan Van Tam, Ab Osterhaus and Derek J. Smith conducted a 
new collaborative study based on the same data used by Cochrane, but applied an 
alternative and simpler framework of analysis. Van Tam: “We took the same 75 eligible 
studies and first corrected the assignment errors of studies to circulation periods. The 
outcomes were then re-plotted on the basis of simple, policy-relevant scenarios: laboratory-
confirmed influenza, syndromic influenza-like illness, complications and no virus circulation.”  
 
With an efficacy against laboratory-confirmed influenza of around 50 %; against ILI without 
virus confirmation of around 40%; and against influenza-related fatal and non-fatal 
complications of around 30 % (with large dispersion), the revised Cochrane study now 
provides ample evidence of the efficacy of influenza vaccines in the elderly. Biological 
vaccine efficacy against infection is between 50% and 70%. 
 
The safety issue 
 
There is not only confusion about vaccine efficacy. Safety is also an issue. Seasonal trivalent 
influenza vaccines may cause reactions at the injection site, such as redness, pain and 
swelling. Systemic reactions can also occur, but these are usually mild and self-limited: fever, 
general malaise, myalgia and ocular or respiratory symptoms, such as red eyes, a hoarse 
voice or a cough, especially with aerosol vaccines. Other and rarer side effects include the 
Guillain-Barré syndrome and there were also reports of febrile seizures in Australia in 2010.  
 
Arguments against vaccination regularly cite their so-called lack of safety, frequently 
associating a number of contentious health issues with vaccination and also claiming that 
seasonal vaccination can actually cause serious illnesses instead of preventing it. In order to 
deal with these exaggerations and misinterpretations, which cause anxiety or make existing 
anxiety worse, it is necessary to reframe opinions with objective findings.  
 
“Safety issues may have a considerable impact on vaccine uptake in vulnerable populations, 
which emphasizes the urgent need for risk monitoring and the benefits it can yield. Once 
people have a negative idea of vaccination, it is difficult to change,” says Miriam 
Sturkenboom of the Department of Medical Informatics at the Erasmus Medical Centre in 
Rotterdam. In 2014, the European Medicines Agency issued a new guidance document on 
the subject of safety. This document said that: ‘Pharmaco-vigilance systems for influenza 
vaccines need the capability to rapidly detect and evaluate new safety concerns each 
season.’ Sturkenboom: “The new surveillance request should mitigate risks before the peak 
period of seasonal immunization. This is important, because mass immunization takes place 
over a relatively short period of time. There is also a multiplicity of seasonal c-vaccine 
products on the market.  Any change in production processes might affect the immune 
response. The early mitigation of risk is also important because of the expansion of target 
groups to pregnant women and children. The objective of the new guidance is to rapidly 
detect a clinically significant change in reactogenicity; in other words, local, systemic or 
allergic reactions. Companies are expected to report their results within 1 month following 
the start of influenza vaccination.”  
 
The pandemic H1N1 influenza vaccine was responsible for one of the major safety 
surveillance issues of the last years, after the Guillain-Barré syndrome concern with the 
swine flu virus in 1976. Both the adjuvanted and non-adjuvanted pandemic H1N1 vaccines 
were licensed with fast track procedures. As a result of this fast tracking, safety data was 
limited. The non-adjuvanted H1N1 vaccines were expected to have a similar safety profile to 
the seasonal influenza vaccines. “The concern about GBS was one of the key elements of the 
pandemic risk management programme,” says Sturkenboom. The active surveillance of 
Guillain-Barré showed a global study difference between adjuvanted and non-adjuvanted 
vaccines. Most of the studies showed a significantly increased risk. But stratification between 
adjuvanted and non-adjuvanted vaccines indicated that the risk was highest for the non-
adjuvanted vaccines. In Europe and Canada where oil-in-water adjuvants were used to 
increase response and save on antigens, there was no increased risk. In the US, where non-
adjuvanted vaccines were used, the risk increased. Sturkenboom: “The question is whether 
this augmented risk is due to the non-adjuvanted vaccine itself or its lower effectiveness 
compared to the adjuvanted vaccine. It also continues to be very difficult to adjust for the 
fact that the wild type influenza virus has an effect that can cause the Guillain-Barré 
syndrome.”  
 
Awareness bias  
 
Just signalling a potential problem may also increase the number of problem cases reported. 
For example, there was an unexpected increase in the occurrence of narcolepsy cases in 
Sweden and Finland during the pandemic. The first suggestion that narcolepsy - a chronic 
sleep disorder characterised by overwhelming daytime drowsiness and sudden 'attacks' of 
sleep - might be associated with the Pandemrix vaccine was made in Finland in February 
2010. From August 2010 onwards, the issue received regulatory attention and each time 
new news broke the number of Google hits on the term 'narcolepsy' peaked. Likewise, the 
number of spontaneous reports by physicians detecting a Pandemrix-narcolepsy association 
also suddenly increased.  
 
Narcolepsy is a disease that in other circumstances takes a long time to be diagnosed 
accurately. The lag time average between onset and diagnosis is 10 years. Sturkenboom: “It 
is very clear that as soon as there is a lot of talk about narcolepsy, people with similar 
problems will seek medical attention more quickly. So you can expect a shortening of the 
time between onset and diagnosis. But if you want to study the possible relationship 
between the vaccine and the safety issue, in this case narcolepsy, you don’t want to get 
mixed up in the media-effect. For patients, it is very difficult to remember the exact moment 
when their sleeping problem started. Everybody will say that it started after vaccination, not 
in the least so that they can file a claim. One methodological solution to potential awareness 
bias is to exclude all cases diagnosed after the start of the attention wave.”  
 
Many studies were conducted to determine whether the association was real or media-
inspired. “Several studies show strong associations, leading to a general belief that there is a 
causal association. But all in all, the findings remain inconclusive. No study has properly 
addressed potential detection bias. And several studies suffer from ascertainment bias. For 
this reason, additional studies are needed that avoid detection and awareness bias,” says 
Sturkenboom. The supposed association has already had a negative effect on vaccination 
uptake in Finland, especially in children aged from 6 to 35 months. Compared to 2009-2010 
or even the 2008 and 2007 flu seasons, vaccine uptake has dropped by half, and is now well 
below 20%. The vaccination rate in the elderly has also been declining in the post-pandemic 
years.   
 
Nothing is ever 100%  
 
Vaccines really work. But the individual degree of effectiveness in a person always depends 
on who is vaccinated and how well the vaccine matches the circulating flu strain. This is 
inevitable, given the complex relationship between biological vaccine efficacy and the real 
world context. Vaccines trigger the immune system. The resulting protection effectiveness 
always depends on the ability of the immune system of the vaccinated person to respond. As 
a consequence, for some people - the elderly, children younger than 2 years and the 
sufferers of certain chronic illnesses - flu shots might not work as well as for healthy young 
adults. This continues to be the biggest difficulty in encouraging more vaccination: at the 
present time influenza vaccination cannot guarantee a 100 % effective and safe result - and 
this is what is needed to silence the critical voices. “Very few things in medicine are 100 % 
safe and effective, just as very few things in communication are 100 % safe and effective,” 
says John Parrish-Sprowl from the Global Health Communication Centre at the Indiana 
University, School of Liberal Arts, USA. “Looking for the perfect message is simple and 
elegant, but its existence depends on certainty, which in today's world is an illusion. Besides, 
the more potential risks that the state and the doctors present to the public, the more 
people are going to stick to the idea that not vaccinating is the right choice.” 
 
“Vaccines are widely recognized by health authorities and the medical community as a major 
tool for achieving public health successes, such as the eradication of smallpox. Yet for many 
individuals, this is not sufficient evidence for them to embrace vaccination wholeheartedly. 
They doubt the beneﬁts of vaccines, worry about their safety and question the need for 
them. We refer to this attitude as vaccine hesitancy. An attitude of vaccine hesitancy differs 
from an action of vaccine refusal. Even those who are vaccinated can harbour hesitancy 
towards certain aspects of vaccination. The policy concern is that hesitancy soon becomes 
refusal, as suggested by both theory and experience. This could lead to the emergence of 
unvaccinated clusters, in which disease outbreaks could occur. Moreover, people not only 
make a decision about vaccination for themselves; they also talk about it. Vaccine hesitancy 
is an increasing global phenomenon. And research consistently suggests that just providing 
accurate scientific information will not stop this trend, much less reverse it.” 
 
Health communication strategy 
 
“We will have to come up with something different,” Parrish-Sprowl continues. 
“Communication should never be limited to giving the naked scientific facts and figures. 
Public health communication needs to shift its perspective from 'talking at people' to 'talking 
with people'. Scientists have to understand that there is no such thing as one-way 
communication. Even so, the transmission model still persists, because intellectual history 
has led to the development of the practices that maintain this pattern of behaviour. It 
always works to some degree, and so we keep trying to perfect it. This is a mistake.” 
Communication is inherently relational, which means that in order to be listened to, you first 
have to relate to your public. “We must engage in conversation with the public. We need 
dialogue, both electronic and face-to-face. And when necessary, the trajectory of this 
conversation should be adjusted to maintain the trajectory towards our goal.”  
 
Various changes need to be implemented in health communication strategies for vaccines: a 
change in the communication strategic planning process; collaboration with others, such as 
healthcare workers, community leaders and teachers; greater focus on training and the 
development of new conversational skills; a different allocation of resources; and new 
metrics of evaluation. Parrish-Sprowl: “The internet and social media enable large-scale 
conversations. People are discussing issues in many different ways, the ways they prefer. We 
can observe these conversations and, more importantly, be pro-active in them. But this pro-
active social media strategy needs to be combined with a face-to-face-strategy. In the UK, 
visiting nurses are sent into houses to explain to people how they can use medical 
technology. We know intuitively that face-to-face conversations are better for dealing with 
people's fears. Research supports this approach. It is not about what is said, but about how it 
is said. Everybody knows how communication works. But as soon as we become 
professionals, we forget. One of the challenges is to remember what we already know.” 
 
SPI Lessons learned 
 
Despite the strong evidence for the burden and its severity, vaccine uptake remains low. 
And the collection of accurate information about vaccine uptake is still hampered by the 
absence of monitoring systems. 
 
Universal recommendations could be very useful, especially from a complexity point of 
view. But even then, the prioritising of certain groups may still need to be possible. 
 
With an efficacy against laboratory-confirmed influenza of around 50 %; against ILI without 
virus confirmation of around 40%; and against influenza-related fatal and non-fatal 
complications of around 30 % (with large dispersion), the revised Cochrane study now 
provides ample evidence of the efficacy of influenza vaccines in the elderly. Biological 
vaccine efficacy against infection is between 50% and 70%.  
 
Safety issues may have a considerable impact on vaccine uptake in vulnerable populations, 
which emphasizes the need for the rapid benefits of greater risk monitoring.  
 
Communication should never be limited to giving the naked scientific facts and figures. 
Scientists must engage in conversation with the public. There must be dialogue, both 
electronic and face-to-face. The internet and social media enable conversations to be 
conducted on a wide scale. Having said this, research confirms that face-to-face 
conversations are better for dealing with people's fears. 
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